Kornimate/medical-research-clean huggingface dataset:
a study of brii-296 in adults with severe postpartum depression (ppd)

Conditions: Severe Postpartum Depression

Summary: the primary purpose of this study is to evaluate the safety and tolerability of brii-296 administered by 2 intramuscular injections, administered with depo medrol as assessed by the incidence of adverse events, changes from baseline in vital signs, pulse oximetry, clinical laboratory evaluations, electrocardiograms (ecgs), stanford sleepiness scale (sss), glasgow coma scale (gcs) in conjunction with clinical assessment, and suicidal ideation using the columbia suicide severity rating scale (c-ssrs).


Eligibility criteria:
inclusion criteria: * participant either must have ceased lactating at screening or is still lactating actively breastfeeding at screening , must agree temporarily cease giving breast milk to her infant(s) * participant has had a major depressive episode that began no earlier than the third trimester and no later than the first 4 weeks following delivery, as diagnosed by the structured clinical interview for diagnostic and statistical manual of mental disorders (dsm-5) * participant was \<12 months postpartum * participant is amenable to intramuscular administration of investigational product on day 1 and remaining inpatient until at least day 4 exclusion criteria: * active psychosis * attempted suicide associated with current episode of postpartum depression * medical history of seizures * medical history of bipolar disorder, schizophrenia, and/or schizoaffective disorder

Keywords: treatment
current treatment methods of idiopathic intracranial hypertension

Conditions: IIH - Idiopathic Intracranial Hypertension

Summary: aim of the study : 1. to determine the response to each treatment plan. 2. to determine when to choose specific treatment method. 3. to determine complication of each type of treatment method

idiopathic intracranial hypertension (iih) is caused by an elevation of intracranial pressure (icp). the condition mainly affects obese young women of childbearing age. in a recent study in the united kingdom university of kentucky urokinase, the estimated annual incidence was 4.7 % which represents a growth of 108% in 14 years, and parallels the growth of obesity prevalence . the combination of raised intracranial pressure, without hydrocephalus or mass lesion, normal cerebrospinal fluid (csf) composition and where no underlying aetiology is found are accepted criteria for the diagnosis of iih. the two most prominent symptoms of iih are progressive visual deterioration and chronic headache, although additional symptoms including cranial nerve palsies, cognitive deficits, tinnitus and olfactory dysfunction are frequently also part of the clinical presentation. while the visual dysfunction is known to largely result from a pressure-induced papilledema, the origin of the iih-related headache is less clear and therapeutic approaches are less investigated. the conventional treatment for iih involves weight loss, steroids, diuretics, and serial lumbar punctures and surgical treatment. surgical intervention should be conducted as soon as medical treatment fails. it is not acceptable to delay the intervention for patient with sever visual deterioration . therefore surgery is indicated once visual loss continues despite optimum medical therapy . medical treatment with acetazolamide and serial lumbar punctures represent the initial management, in such cases preserving surgery to non-responding cases and those who cannot tolerate medical treatment. surgical treatment include lumboperitoneal shunt insertion , navigation guided ventriculo-peritoneal shunt ,endovascular stenting of sinuses in cases of sinus thrombosis and stenosis .

Eligibility criteria:
inclusion criteria: * patient has symptoms of increased intracranial pressure with :- * papilledema, * normal neurological examination,(except 6th nerve palsy), * elevated opening pressure( \>=25 cm) csf, * normal csf content exclusion criteria: * any patient diagnosed with increased intracranial pressure due to: * sinus thrombosis or stenosis will be excluded from this study and .accordingly endovascular stenting as a method of treatment will be excluded from this study.
dermoscopy in nails

Conditions: Vitiligo; Healthy

Summary: study types and frequency of nail changes in patients with vitiligocompared to healthy subjects

dermoscopy is a noninvasive diagnostic tool that is currently being used for different skin lesions, several inflammatory \& infectious diseases, and skin appendages disorders. ") in daily practice, dermoscopy may confirm clinical diagnosis and guides in the management of nail diseases, permitting a better visualization of symptoms. (2) nail dermoscopy (onychoscopy) was initially used only in the assessment of nail pigmentation, but now it is widely utilized for the evaluation of many nail disorders. (3) it enhances visible nail features; however, it can also help identify additional unique and fascinating features not visible to the naked eye. 2) vitiligo is an acquired dyschromia of the skin in which there is loss of epidermal melanocytes the prevalence of vitiligo is approximately 0.1 - 2% worldwide. (5) vitiligo is classified as segmental, acrofacial, generalized, and universal and less commonly mucosal and trichome. vitiligo has been described as a systemic disease. it has been associated with other autoimmune disorders as diabetes (dm), lupus, psoriasis, alopecia areata (aa), hashimoto thyroiditis, and gravesdisease. nails can show changes in association with many disorders such as renal, hepatic, pulmonary, autoimmune and collagen diseases. (67) dermoscopic nail changes has been reported in several autoimmune disorders such as, in dm; longitudinal striations, pitting, onycholysis, \& splinter hemorrhage, (® in aa; scaly cuticle, punctate leukonychia, oncholysis, \&oncychoschizia®and in collagen vascular disorders; dilated capillaries, capillary dropout, and avascular areas. (10) to the best of our knowledge, dermoscopic nail changes in vitiligo haven't been reported yet. however, few studies had discussed clinical nail changes in vitiligo such as: (11) longitudinal ridging, absent lunula, leukonychia, pitting, in addition to less common nail changes such as flag sign and terry's nails

Eligibility criteria:
inclusion criteria: * age adults patients 12-50 years old all types of vitiligo: focal, generalized, acrofacial, segmental exclusion criteria: * patients older than 50 (because of aging's nail changes patients with autoimmune disorders patients using systemic medication for any reason including oral contraceptive pill
uveal melanoma - comparative study

Conditions: Uveal Melanoma

Summary: the progress of uveal melanoma is typically monitored with sonography by experienced onco-ophthalmologists. however, there is evidence that twodimensional measurements in color fundus photography match precisely with sonography measurements. this study aims to compare sonography and color fundus photography measurements in order to evaluate the feasibility of monitoring of uveal melanoma with color fundus photography.


Eligibility criteria:
inclusion criteria: * diagnosis of uveal melanoma exclusion criteria: * inadequate or missing information on the clinical course in patient charts * imaging not feasible due to any reason.
dyspnea in stable patients with coronary artery disease.

Conditions: Dyspnea; Coronary Artery Disease

Summary: single-centre prospective study to characterize causes of dyspnea in stable patients with coronary artery disease and evaluate the possibility to determine the cause of dyspnea before in-depth examination.

stable patients with dyspnea and coronary artery disease will be included in this single-centre prospective study. in addition to routine clinical examination patients will be interviewed to determine the nature of shortness of breath, angina, presence of chronic heart failure or anxiety using the medical research council dyspnea scale, the visual analog scale of dyspnea, borg scale, modified "dictionary" of dyspnea, g. rose questionnaire, seattle angina questionnaire, framingham criteria for chronic heart failure and the shock scale. during the subsequent in-depth examination including thyroid hormones, nt-probnp, hstroponin, ecg monitoring, six-minute walk test, stress-echo with a diastolic stress test, spirometry and coronary angiography (if necessary) main reason for dyspnea will be established. possibilities of early (before in-depth examination) determination the reason for dyspnea in stable patients with coronary artery disease will be evaluated.

Eligibility criteria:
inclusion criteria: 1. stable patients with shortness of breath and established diagnosis of coronary artery disease (at least 1 of the following signs): * history of myocardial infarction; * typical angina without suspected other cause of pain; * myocardial ischemia documented by ecg changes during symptoms and/or by results of the stress test; * coronary artery stenosis \>50% according to coronary angiography. 2. signed informed consent. exclusion criteria: 1. acute coronary syndrome (myocardial infarction, unstable angina) in the previous month. 2. hospitalization with decompensation of chf in the previous 6 months (including chf decompensation as the main reason for current hospitalization). 3. diseases with an unfavourable prognosis (terminal ckd, chf nyha iv, a lung disease with severe respiratory failure). 4. contraindications to bicycle stress echocardiography. 5. atrial fibrillation at the time of hospitalization, when the decision not to restore the sinus rhythm. 6. mental illnesses and disorders, dementia, drug or alcohol dependence. 7. known oncological diseases.

Keywords: dyspnea stable coronary artery disease heart failure diastolic stress test
clinical comparison of 2 daily disposable toric soft contact lenses

Conditions: Refractive Errors; Astigmatism

Summary: the purpose of this study to evaluate the overall performance of precision1™ for astigmatism contact lenses with myday® toric contact lenses.

subjects will be expected to attend 4 visits and wear study lenses daily for approximately 10 hours per day. on the day prior to the week 1 follow-up visit of each crossover period, subjects will be asked to wear the respective study lens for at least 16 hours. the expected duration of subject participation in the study is approximately 3 weeks.

Eligibility criteria:
key inclusion criteria: * successful wear of toric soft contact lenses in both eyes for a minimum of 5 days per week and 10 hours per day during the past 3 months. * willing to wear study contact lenses for at least 16 hours on the day prior to the week 1 follow up visit of each lens type. * other protocol-defined inclusion criteria may apply. key exclusion criteria: * current/previous wear of precision1 for astigmatism or myday toric contact lenses. * current wear of spherical contact lenses. * wears habitual contact lenses in an extended wear modality (routinely sleeping in lenses for at least 1 night per week). * other protocol-defined exclusion criteria may apply.

Keywords: contact lenses daily disposable
tranexamic acid in the treatment of residual chronic subdural hematoma -2

Conditions: Chronic Subdural Hematoma

Summary: chronic subdural hematoma (csdh), a common disease after minor head trauma, is characterized by blood collection in the subdural space, which can result in severe neurological impairment. the current standard of care is the surgical evacuation of csdh. although clinical and surgical outcomes are satisfying in most cases, considerable morbidity, mortality and recurrence rates of 3-31% are frequently reported. therefore a non-surgical approach to treat csdh is desirable. tranexamic acid (txa), an antifibrinolytic drug, has been shown to decrease hematoma volume in a small cohort of csdh patients. the present study is designed to test the hypothesis that txa can reduce the volume of csdh. volume measurements of residual csdh after burr-hole surgery will be performed to quantify treatment success. the trial is designed as a double-blinded randomized controlled trial, where half of the patients will be assigned to daily intake of txa, whereas the other half will receive placebo. the primary endpoint is defined as volume change in milliliter after 4-8 weeks of treatment. secondary endpoints are hematoma volume at 8-12 weeks, patient safety, the number of patients with resolution of the csdh after 4-8 and 8-12 weeks of study participation, the neurological outcome, the rate of reoperation, the time to reoperation, drug safety and compatibility, and participant quality of life (qol).


Eligibility criteria:
inclusion criteria: * diagnosis of chronic subdural hematoma (csdh) * written informed consent (patient, power of attorney or substitute decision maker) * competence to take study medication properly and regularly or access to caregiver that is able to comply with accurate study medication administration exclusion criteria: * hypersensitivity to txa or any of the ingredients * pregnancy * irregular menstrual bleeding with unidentified cause * acquired colour vision disturbances * acute and chronic renal insufficiency indicated by gfr ≤ 30 ml/min * hematuria, caused by diseases of renal parenchyma * concomitant intake of hormonal contraceptives, factor ix complex concentrates, and anti-inhibitor coagulant concentrates (factor vii, activated factor ix) * history of angioplasty with cardiac stent placement, or cardiac (including mechanical) valve placement * active history of stroke (hemorrhagic and ischemic), or subarachnoid hemorrhage, within the past 6 months * consumption coagulopathy/disseminated intravascular coagulation (dic) in the last 7 days * history of malignant brain tumors (glioma, metastasis and others) or seizures within the 6 months * contraindication to stopping full therapeutic doses of non-asa antiplatelets, warfarin, rivaroxaban, apixaban, dabigatran, or other anticoagulant for 2 weeks after surgery * inability of oral drug intake or missing support to guarantee oral drug intake * sdh as caused by intracranial hypotension resulting from csf shunt placement

Keywords: tranexamic acid chronic subdural hematoma neurosurgery
evaluation of the "housing first program" in homeless patients with severe mental disorders in france

Conditions: Subnormal; Mental, Severe

Summary: as mental health care shifted from state psychiatric hospitals to the community in france and western countries, the mental health system became inevitably involved in housing as it strove to meet the broader psychosocial needs of consumers. simultaneously, as many consumers found themselves unable to find stable living in the community and struggling with addictions, they became a significant subgroup within a larger homeless population, which has received increasing policy attention over the past three decades. there are two distinct service models for adults who have severe mental illness and are homeless: the residential continuum model and the housing first model.


Eligibility criteria:
inclusion criteria: aged over 18; * who are absolutely homeless or precariously housed. absolutely homeless is defined as having had no fixed place to stay for at least the past seven nights with little likelihood of finding a place in the coming month. precariously housed is defined as being housed a in single room occupancy, rooming house, or hotel/motel as a primary residence and in the past year having experienced two or more episodes of being absolutely homeless or one episode of being absolutely homeless that lasted for more than four weeks in the preceding 12 months. * living with schizophrenia or bipolar disorder (diagnosis of dsm-iv); * with a sufficient understanding of written and spoken french to be able to provide informed consent and to participate to face-to-face interviews; * affiliated to a social protection; * who have lived in the city targeted for at least 6 months and willing to stand in the city during the 2 next years; * with a global score measured on multnomah community ability scale (mcas) (scale \<=62 (high need criteria)); * hospitalized at least twice on the past 12 months or held in prison on the past 24 months or presenting substance or alcohol abuse or dependence (high need criteria). exclusion criteria: * being considered unable to provide informed consent; * having dependent children; * pregnancy; * or a dsm-iv axis i diagnosis other than schizophrenia or bipolar disorder
effect of metformin on patients with polycystic ovary syndrome

Conditions: PCOS (Polycystic Ovary Syndrome) of Bilateral Ovaries

Summary: the purpose of the study is to understand the effect of metformin on patients with pcos.

this study aims to evaluate the effects of metformin on reproductive endocrine and reproductive outcomes in women with pcos, and to explore its underlying mechanisms to provide the intervention strategies for pcos.

Eligibility criteria:
inclusion criteria: 1. individuals who are 20 to 40 years old, planning to become pregnant or infertile women. 2. individuals who are diagnosed as pcos according to the revised 2003 rotterdam diagnostic criteria: if 2 out of 3 criteria are met: 1) oligo- and/or anovulation; 2) clinical and/or biochemical signs of hyperandrogenism; 3) polycystic ovaries, and exclusion of other aetiologies (congenital adrenal hyperplasia, androgen-secreting tumors, cushing's syndrome). 3. individuals who can insist on continuous monitoring in the outpatient clinic. individuals who are not participating in other research projects currently or 3 months before the intervention. exclusion criteria: 1. individuals who suffering from other diseases that may cause hyperandrogenism and ovulation abnormalities. 2. individuals who are during pregnant, lactation or menopause. 3. individuals who currently receiving weight-loss drugs or surgery or within the past 2 months. 4. individuals who take niacin, nicotinamide, or other vitamin b3-related supplementation currently or within the past 2 months. 5. individuals who need regular medication to treat chronic diseases such as diabetes, hypertension, gout, hyperuricemia, etc. 6. use of medications that affect hormone levels, appetite, carbohydrate absorption, and metabolism within the past 2 months. 7. individuals with severe liver diseases or kidney disease that are ineligible to participate in the study. 8. a medical history of severe cardiovascular and cerebrovascular diseases. 9. individuals who currently suffer from severe gastrointestinal diseases or undergo gastrointestinal resection that may affect nutrient absorption. 10. individuals who drink more than 15g of alcohol per day or have a smoking habit. 11. individuals who need drug treatment for any mental illness such as epilepsy and depression. 12. cancer patients. 13. individuals who suffer from infectious diseases such as hepatitis b, active tuberculosis, aids, etc.
dexamethasone for the prevention of postoperative cognitive dysfunction

Conditions: Postoperative Cognitive Dysfunction

Summary: this study aims to evaluate the possible effect of dexamethasone on prevention of cognitive dysfunction in the postoperative period of elderly patients undergoing to surgery under general anesthesia.

postoperative cognitive dysfunction is related with the use of opioids in the postoperative period, lack of physical activity, fatigue, postoperative pain and quality of life. the use of corticosteroids preoperatively reduces postoperative pain, fatigue, nausea and vomiting in the postoperative period and is frequently used as an adjuvant in anesthesia. this study aims to evaluate the possible effect of dexamethasone on prevention of cognitive dysfunction in the postoperative period of elderly patients undergoing to surgery under general anesthesia.

Eligibility criteria:
inclusion criteria: * patients over 60 years, * underwent surgery for inguinal hernia repair, nissen procedure, cholecystectomy or other surgeries midsize under general anesthesia and hospital stay expected within 72 hours. exclusion criteria: * age less than 60 years, * history of brain disease or dementia, other psychiatric disorders that affect cognition, * lack of proficiency in portuguese, * use of corticosteroids or opioid preoperatively.

Keywords: dexamethasone postoperative cognitive dysfunction general anesthesia neuropsychological tests
evaluation of a multi-professional breathlessness service for patients with breathlessness due to any advanced disease

Conditions: Breathlessness; COPD; Cancer; Chronic Heart Failure; Interstitial Lung Disease

Summary: breathlessness is a common and distressing symptom in patients with advanced diseases like cancer, chronic obstructive pulmonary disease (copd), chronic heart failure (chf) or lung fibrosis, which broadly impacts on patients' quality of life and may result in high burden for carers. this single-blinded randomized controlled fast track trial evaluates the effectiveness of a multi-professional breathlessness service in patients with advanced and chronic diseases. the intervention group will get immediate access to the breathlessness service whereas the control group will receive standard care and get access to the service after a waiting time of eight weeks. primary endpoints are mastery of breathlessness and quality of life, measured with the crq (chronic respiratory questionnaire) as well as the reduction of symptom burden of patients and burden of carers. the evaluation of the cost effectiveness of the breathlessness service from the perspective of the german health system is a further study aim.


Eligibility criteria:
inclusion criteria: * patients affected by breathlessness due to any advanced life-limiting and progressive disease, despite treatment of the underlying condition and * patients capable (in a cognitive and functional manner) to participate in the intervention including outpatient clinic and physiotherapist visits as well as self- management * if patients are suffering from acute exacerbations of the underlying conditions, they are put on a waiting list for two to four weeks and are then entered into the trial. exclusion criteria: * patients suffering from breathlessness due to chronic hyperventilation syndrome, asthma or any other unknown cause * cancer patients under concurrent initial or full dose systemic treatment or radiotherapy (except on maintenance therapy) * patients participating in any trial targeting the treatment of underlying conditions/ illness

Keywords: quality of life palliative therapy outpatient services